Segment and Other Revenue Information - Statement of Income Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 02, 2016	Sep. 27, 2015	Oct. 02, 2016		Sep. 27, 2015
Segment Reporting Information [Line Items]
Employee termination costs				$ (17)
Exit costs	[1]			3
Accelerated depreciation				5
Provision for losses on inventory				65		$ 59
Consulting fees				14
Charges with changes in operating model		$ 3		4
Gain (loss) recognized related to divestitures	[2]	0	$ 0	27	[3]	0
Identifiable intangible asset impairment charges	[3]	1	0	1		2
Investor related costs						3
In Process Research and Development
Segment Reporting Information [Line Items]
Identifiable intangible asset impairment charges						2
Certain Significant Items
Segment Reporting Information [Line Items]
Stand-up costs		1	22	18		84
Zoetis Initiatives
Segment Reporting Information [Line Items]
Employee termination costs		4	8	(16)		271
Exit costs		1
Accelerated depreciation		2
Consulting fees		4
Aggregate amount of all charges			24			317
Operational Efficiency
Segment Reporting Information [Line Items]
Employee termination costs		4	8	(22)		261
Exit costs		1	0	4		0
Accelerated depreciation		0	0	1		0
Provision for losses on inventory		1	5	1		5
Gain (loss) recognized related to divestitures	[1]	0	0	(27)		0
Employee Termination Costs
Segment Reporting Information [Line Items]
Employee termination costs				(20)
Employee Termination Costs | Zoetis Initiatives
Segment Reporting Information [Line Items]
Employee termination costs		3		(20)
Employee Termination Costs | Operational Efficiency
Segment Reporting Information [Line Items]
Employee termination costs	[4]	3	0	(26)		228
Euro Member Countries, Euro
Segment Reporting Information [Line Items]
Revenues denominated in Euros		$ 157	$ 139	$ 469		$ 425

[1] For the nine months ended October 2, 2016, represents the net gain on the sale of certain manufacturing sites and products, partially offset by the loss on the sale of our share of our Taiwan joint venture, as part of our operational efficiency initiative.

[2] For the nine months ended October 2, 2016, represents the net gain on the sale of certain manufacturing sites and products, partially offset by the loss on the sale of our share of a Taiwan joint venture, as part of our operational efficiency initiative.

[3] For the three and nine months ended October 2, 2016, represents an impairment of finite-lived trademarks related to a canine pain management product. For the nine months ended September 27, 2015, represents an impairment of IPR&D assets related to the termination of a canine oncology project.

[4] For the nine months ended October 2, 2016, includes a reduction in employee termination accruals primarily as a result of higher than expected voluntary attrition rates experienced in the first half of 2016.